Protagonist Therapeutics, Inc. PTGX
135.86 USD +1.00 (+0.74%)
Nov 12, 2026, 1:40 PM EST
131.27 Day range 138.82
77.00 52-week range 160.81
- YTD
- +55.55%
- 1 year
- +60.11%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.
zacks.com Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates Protagonist Therapeutics (PTGX) came out with quarterly earnings of $3.07 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to a loss of $0.62 per share a year ago.- benzinga.com TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160 TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
benzinga.com Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.28% on an annualized basis producing an average annual return of 19.88%. Currently, Protagonist…
benzinga.com UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184 UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
benzinga.com Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190 Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.
benzinga.com Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist…
benzinga.com Protagonist Therapeutics Announces $300M Buyback Plan Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its…
benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
benzinga.com Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…
benzinga.com BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190 BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
benzinga.com Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.- benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
- benzinga.com BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178 BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
benzinga.com Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.- benzinga.com Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170 Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
- benzinga.com Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173 Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $118 to $173.
benzinga.com This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.- benzinga.com Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186 Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.
benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
benzinga.com Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over…- benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.
- benzinga.com Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145 Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.
benzinga.com This $300 Million Biotech May Be Deeply Mispriced: Analyst Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
benzinga.com AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
benzinga.com Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.- benzinga.com Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology…
- benzinga.com Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $137 Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $120 to $137.
- benzinga.com Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118 Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.
benzinga.com Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over…- benzinga.com Protagonist Therapeutics Exercises Opt-Out Of Rusfertide 50:50 Profit And Loss Sharing Arrangement With Takeda, Eligible For Up To $400M In Opt-Out Payments By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the…
- benzinga.com Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $121 Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $110 to $121.
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com Clear Street Maintains Buy on Protagonist Therapeutics, Raises Price Target to $116 Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $104 to $116.- benzinga.com Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderate-to-severe plaque psoriasisResults…
- benzinga.com Leerink Partners Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $110 Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $107 to $110.
- benzinga.com Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $125 Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $115 to $125.
- benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $119 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $113 to $119.
benzinga.com Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.- benzinga.com Goldman Sachs Maintains Neutral on Protagonist Therapeutics, Raises Price Target to $95 Goldman Sachs analyst Richard Law maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Neutral and raises the price target from $65 to $95.
- benzinga.com Takeda And Protagonist Say FDA Grants Priority Review For Rusfertide As Potential First-In-Class Therapy For Polycythemia Vera, Backed By Phase 3 VERIFY Data Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily…
benzinga.com A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - benzinga.com TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $100 TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $90 to $100.
- benzinga.com Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $113 Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $108 to $113.
- benzinga.com Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $112 Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $102 to $112.
benzinga.com Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways - benzinga.com Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.24) by 191.14 percent. This is a 134.85 percent decrease over…
- benzinga.com Jefferies Maintains Buy on Protagonist Therapeutics, Raises Price Target to $118 Jefferies analyst Roger Song maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $95 to $118.
benzinga.com Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views - benzinga.com HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $117 HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $80 to $117.